Immix Biopharma (IMMX) Exchange Rate Effect (2021 - 2026)
Immix Biopharma (IMMX) posted Exchange Rate Effect of -$12813.0 for Q1 2026, down 9.09% sequentially from -$11745.0 in Q4 2025, and down 60.16% YoY from -$32163.2 in Q1 2025.
Powered by 
Analysis
Immix Biopharma (IMMX) Exchange Rate Effect (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Exchange Rate Effect for 6 years, with the latest figure at -$12813.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 60.16% year-over-year to -$12813.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$971.0 (up 22.69% YoY) and the FY2025 annual result came in at $3842.0, up 206.07% from the prior year.
- Exchange Rate Effect fell to -$12813.0 in Q1 2026 per IMMX's latest filing, from -$11745.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $44139.0 in Q2 2025 and troughed at -$25128.0 in Q4 2024.
- A 5-year average of -$648.53 and a median of -$5304.0 in 2022 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2023 and 2024: Exchange Rate Effect soared 20028.66% in 2023, then sank 1744.48% in 2024.
- Over 5 years, Exchange Rate Effect stood at -$157.0 in 2022, then jumped by 20028.66% to $31288.0 in 2023, then sank by 180.31% to -$25128.0 in 2024, then soared by 53.26% to -$11745.0 in 2025, then decreased by 9.09% to -$12813.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$12813.0, -$11745.0, and -$20552.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Immix Biopharma | 889.29 Mn | 889.29 Mn | - | 24,665.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24,665.00 |
| Mar 31, 2026 | -12,813.00 |
| Dec 31, 2025 | -11,745.00 |
| Sep 30, 2025 | -20,552.00 |
| Jun 30, 2025 | 44,139.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -25,128.00 |
| Sep 30, 2024 | 22,962.00 |
| Jun 30, 2024 | 8,910.00 |
| Mar 31, 2024 | -10,366.00 |
| Dec 31, 2023 | 31,288.00 |
| Sep 30, 2023 | -11,771.00 |
| Jun 30, 2023 | 14,137.00 |
| Mar 31, 2023 | -562.00 |
| Dec 31, 2022 | -157.00 |
| Sep 30, 2022 | -23,341.00 |
| Jun 30, 2022 | -5,304.00 |
| Mar 31, 2022 | -2,722.00 |
| Dec 31, 2021 | 621.00 |
| Sep 30, 2021 | -3,498.00 |